{
    "clinical_study": {
        "@rank": "73765", 
        "arm_group": [
            {
                "arm_group_label": "AV7909 (Day 0 and 14)", 
                "arm_group_type": "Experimental", 
                "description": "Route of administration:  Intramuscular Dose: 0.5 mL Schedule:  Day 0 and Day 14"
            }, 
            {
                "arm_group_label": "AV7909 (Day 0 and 28)", 
                "arm_group_type": "Experimental", 
                "description": "Route of administration:  Intramuscular Dose: 0.5 mL Schedule:  Day 0 and Day 28"
            }, 
            {
                "arm_group_label": "AV7909 (Day 0, 14, and 28)", 
                "arm_group_type": "Experimental", 
                "description": "Route of administration:  Intramuscular Dose: 0.5 mL Schedule:  Day 0, Day 14,and Day 28"
            }, 
            {
                "arm_group_label": "AV7909 Reduced Dose", 
                "arm_group_type": "Experimental", 
                "description": "Route of administration:  Intramuscular Dose: 0.25 mL Schedule:  Day 0, Day 14,and Day 28"
            }, 
            {
                "arm_group_label": "BioThrax", 
                "arm_group_type": "Active Comparator", 
                "description": "Route of administration:  Intramuscular Dose: 0.5 mL Schedule:  Day 0, Day 14,and Day 28"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the safety and immunogenicity of an anthrax vaccine.\n      The vaccine schedule and dose will also be assessed."
        }, 
        "brief_title": "A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose Levels", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Anthrax", 
        "condition_browse": {
            "mesh_term": "Anthrax"
        }, 
        "detailed_description": {
            "textblock": "The safety and immunogenicity of AV7909 for post-exposure prophylaxis of anthrax will be\n      evaluated using a randomized, parallel-group, active-controlled, double-blind design with\n      three immunization schedules and two dose levels in healthy adult volunteers.  Safety will\n      be assessed by clinical laboratory tests (hematology, serum chemistry, and urinalysis),\n      monitoring of adverse events, vital signs, and physical examinations.  Reactogenicity\n      (systemic and injection site reactions) will be assessed by the subjects using subject\n      e-diaries for 7 days after each immunization and by the investigator at in-clinic visits 7\n      and 14 days after each  immunization, and at other visits, if applicable.  Immunogenicity\n      will be measured as toxin neutralizing antibody (TNA) response and seroconversion rates."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Be 18-50 years old\n\n          -  Be in good health\n\n          -  Have access to a computer and the internet so you can complete a diary\n\n          -  Agree to abstain from sex the first 84 days of the study or practice birth control if\n             you are a woman who is able to get pregnant\n\n          -  Have not donated blood for the previous 8 weeks\n\n        Exclusion Criteria:\n\n          -  A known anaphylactic response, severe systemic response, or serious hypersensitivity\n             reaction to a prior immunization.\n\n          -  A history of latex allergy.\n\n          -  Have received a shot (vaccine), including flu shots, in the past 6 weeks or plan to\n             get a shot for 4 weeks after the last study shot is given.\n\n          -  Have previously served in the military any time after 1990 or plan to enlist in the\n             military from Screening through Day 84.\n\n          -  Prior immunization with anthrax vaccine, recombinant protective antigen (rPA)\n             vaccine, or known exposure to anthrax organisms.\n\n          -  Have participated in anthrax therapeutic or vaccine studies (monoclonal anti-PA or\n             anthrax immune globulins or anthrax vaccines).\n\n          -  Participation in any investigational study involving use of a pharmacological\n             intervention within 30 days before the Screening visit or planning to participate in\n             a study requiring dosing through the 12-month safety follow-up telephone call.\n\n          -  Have a known diagnosis of any immunodeficiency disease including but not limited to:\n             acquired immune deficiency syndrome (AIDS), common variable immunodeficiency disease,\n             immunoglobulin A (IgA) deficiency, or hypogammaglobulinemia.\n\n          -  Past history of significant autoimmune disease such as rheumatoid arthritis, lupus\n             erythematous, psoriasis in the area of vaccinations, or requires immunotherapy,\n             glomerulonephritis, or autoimmune thyroiditis.\n\n          -  Have received immunosuppressive therapy with cytotoxic drugs or Rituximab within the\n             past 2 years.\n\n          -  A history of cytotoxic chemotherapy or radiation therapy.\n\n          -  Chronic (>10 days) daily oral or parenteral corticosteroid therapy in the past 12\n             months.\n\n          -  Any lung disease, including reactive airway disease, which requires the daily use of\n             medications.\n\n          -  A female currently breastfeeding or with a positive pregnancy test.\n\n          -  A history of drug or alcohol abuse within 12 months prior to Screening, or a positive\n             result on a urine drug screen for cocaine, marijuana, opiates, methamphetamines,\n             benzodiazepines, or oxycodone.\n\n          -  Any tattoo or other skin condition in the deltoid region on either arm that may\n             obscure the assessment of the injection sites.\n\n          -  A medical condition that, in the opinion of the PI or designee, could adversely\n             impact the subject's participation or safety or the conduct of the study.\n\n          -  Any planned elective in-patient surgery during the study period."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "168", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01770743", 
            "org_study_id": "EBS.AVA.208 / DMID 11-0055", 
            "secondary_id": "HHSN272201000035C"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "AV7909 (Day 0 and 14)", 
                    "AV7909 (Day 0 and 28)", 
                    "AV7909 (Day 0, 14, and 28)", 
                    "AV7909 Reduced Dose"
                ], 
                "description": "Anthrax Vaccine Adsorbed plus CPG 7909 Adjuvant", 
                "intervention_name": "AV7909", 
                "intervention_type": "Biological", 
                "other_name": [
                    "AV7909 Anthrax Vaccine", 
                    "NuThrax"
                ]
            }, 
            {
                "arm_group_label": "BioThrax", 
                "intervention_name": "BioThrax", 
                "intervention_type": "Biological", 
                "other_name": "Anthrax Vaccine Adsorbed (AVA)"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "post-exposure prophylaxis", 
            "toxin neutralization assay"
        ], 
        "lastchanged_date": "November 19, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33143"
                    }, 
                    "name": "Miami Research Associates"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mount Pleasant", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29464"
                    }, 
                    "name": "Costal Carolina Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Braunfels", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78130"
                    }, 
                    "name": "Central Texas Allergy and Asthma"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Salt Lake City", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84124"
                    }, 
                    "name": "Jean Brown Research"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "5", 
        "official_title": "A Phase 2, Randomized, Parallel-Group, Active-Controlled, Double-Blind Study to Evaluate the Safety and Immunogenicity of AV7909 for Post-Exposure Prophylaxis of Anthrax Using Three Immunization Schedules and Two Dose Levels in Healthy Adult Volunteers", 
        "overall_official": {
            "affiliation": "Emergent BioSolutions", 
            "last_name": "Robert Hopkins, MD, MPH, TM", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Immunogenicity measured by the lower bound (LB) of the 95% confidence intervals (CIs) for the proportion of subjects in each study arm with Day 63 TNA 50% neutralization factor (NF50) values greater than or equal to threshold", 
                "measure": "Toxin Neutralizing Antibody (TNA) Level at Day 63", 
                "safety_issue": "No", 
                "time_frame": "Day 63"
            }, 
            {
                "description": "Safety will be evaluated by adverse events, including assessment of symptoms, physical exam findings, clinical laboratory tests, and vital signs.", 
                "measure": "Number of Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 12 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01770743"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Immunogenicity measured by the percentage of subjects in each study arm with Day 42 TNA NF50 values greater than or equal to threshold", 
                "measure": "TNA Level at Day 42", 
                "safety_issue": "No", 
                "time_frame": "Day 42"
            }, 
            {
                "description": "Immunogenicity measured by the percentage of subjects with Day 28 TNA NF50 values greater than or equal to threshold", 
                "measure": "TNA Level at Day 28", 
                "safety_issue": "No", 
                "time_frame": "Day 28"
            }, 
            {
                "description": "Immunogenicity measured by the percentage of subjects who have seroconverted (defined as a 4-fold increase over Day 0 in TNA NF50 value) at Days 21, 28, 35, 42, 49, 63, and 84", 
                "measure": "TNA Seroconversion Rate", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 84"
            }
        ], 
        "source": "Emergent BioSolutions", 
        "sponsors": {
            "collaborator": {
                "agency": "National Institute of Allergy and Infectious Diseases (NIAID)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Emergent BioSolutions", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}